Kazia Therapeutics Files 6-K Report
Ticker: KZIA · Form: 6-K · Filed: Mar 26, 2024 · CIK: 1075880
| Field | Detail |
|---|---|
| Company | Kazia Therapeutics LTD (KZIA) |
| Form Type | 6-K |
| Filed Date | Mar 26, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, foreign-private-issuer, company-information
Related Tickers: KZA
TL;DR
Kazia Therapeutics (KZA) filed a 6-K, just a routine update for foreign issuers. Nothing major here.
AI Summary
Kazia Therapeutics Limited filed a Form 6-K on March 26, 2024, reporting for the month of March 2024. The company, formerly known as Novogen Ltd, is based in Sydney, NSW, Australia, and operates in the pharmaceutical preparations sector. This filing is a report of a foreign private issuer.
Why It Matters
This filing provides routine updates for investors and regulatory bodies regarding Kazia Therapeutics' status as a foreign private issuer. It confirms their reporting obligations and corporate information.
Risk Assessment
Risk Level: low — This filing is a standard regulatory report for a foreign private issuer and does not contain new material financial or operational information.
Key Players & Entities
- Kazia Therapeutics Limited (company) — Registrant
- Novogen Ltd (company) — Former company name
- 000-29962 (other) — SEC File Number
- 20240326 (date) — Filing Date
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required by the SEC to provide information that the issuer has made or is required to make public pursuant to the laws of its home country, or that it has filed or will file with a stock exchange on which its securities are traded.
When was Kazia Therapeutics Limited previously known as?
Kazia Therapeutics Limited was formerly known as Novogen Ltd, with a date of name change on December 28, 1998.
What is Kazia Therapeutics Limited's primary business sector?
Kazia Therapeutics Limited is in the Pharmaceutical Preparations sector, with SIC code 2834.
Where is Kazia Therapeutics Limited's principal executive office located?
The principal executive office of Kazia Therapeutics Limited is located at Three International Towers, Level 24, 300 Barangaroo Avenue, Sydney NSW 2000.
Does Kazia Therapeutics Limited file annual reports under Form 20-F?
Yes, Kazia Therapeutics Limited indicates it files annual reports under cover of Form 20-F.
Filing Stats: 289 words · 1 min read · ~1 pages · Grade level 12.9 · Accepted 2024-03-26 08:02:03
Filing Documents
- d799876d6k.htm (6-K) — 9KB
- d799876dex991.htm (EX-99.1) — 11KB
- g799876g0326054808442.jpg (GRAPHIC) — 4KB
- 0001193125-24-077110.txt ( ) — 27KB
From the Filing
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2024 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrants name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): INFORMATION CONTAINED IN THIS FORM 6-K REPORT On March 21, 2024, Kazia Therapeutics Limited (the Company) issued a press release titled, Kazia Therapeutics Licenses Paxalisib to Sovargen for Intractable Seizures in Rare Central Nervous System Diseases. A copy of this release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The Company hereby incorporates by reference the information contained herein, including Exhibit 99.1, except for the quotes of Cheolwon Park and Dr. John Friend contained in Exhibit 99.1, into the Companys registration statement on Form F-3 (File No. 333-259224 and 333-276091). EXHIBIT LIST Exhibit Description 99.1 Press Release of Kazia Therapeutics Limited dated March 21, 2024 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Kazia Therapeutics Limited (Registrant) /s/ John Friend John Friend Chief Executive Officer Date: 26 March 2024